BridgeBio Pharma, Inc.
BBIO
$38.34
$0.320.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -375.41% | -57.63% | 8.45% | 53.48% | 74.87% |
| Total Depreciation and Amortization | -19.55% | -13.75% | -6.16% | -3.85% | -2.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 111.47% | 180.35% | -162.18% | -440.33% | 51.07% |
| Change in Net Operating Assets | 48.42% | -41.10% | -263.39% | 1,716.18% | -608.13% |
| Cash from Operations | 9.25% | -56.49% | -24.33% | 165.90% | -52.12% |
| Capital Expenditure | -- | 89.20% | 68.21% | 87.38% | -5,691.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.80% | -964.50% | 0.77% | -29.82% | 83.00% |
| Cash from Investing | -107.01% | -4,804.55% | 1.44% | -26.22% | 85.01% |
| Total Debt Issued | 27.78% | -- | -- | -- | -- |
| Total Debt Repaid | 3.05% | -- | -- | -- | -- |
| Issuance of Common Stock | -98.19% | 755.26% | -99.31% | -- | 119.39% |
| Repurchase of Common Stock | -1,604.77% | 45.05% | 44.71% | -66.00% | -473.44% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.15% | -1,095.70% | 100.00% | -216.27% | -313.37% |
| Cash from Financing | -78.42% | 10,578.24% | -99.77% | -365.39% | 86.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -269.76% | 312.79% | -171.00% | 165.19% | 354.12% |